These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22413811)

  • 21. Botulinum toxin for masseter hypertrophy.
    Al-Muharraqi MA; Fedorowicz Z; Al Bareeq J; Al Bareeq R; Nasser M
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007510. PubMed ID: 19160335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report.
    Mandel L; Tharakan M
    J Oral Maxillofac Surg; 1999 Aug; 57(8):1017-9. PubMed ID: 10437733
    [No Abstract]   [Full Text] [Related]  

  • 23. Botulinum toxin type A treatment for contouring of the lower face.
    Park MY; Ahn KY; Jung DS
    Dermatol Surg; 2003 May; 29(5):477-83; discussion 483. PubMed ID: 12752514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin type A in the management of masseter muscle hypertrophy.
    Castro WH; Gomez RS; Da Silva Oliveira J; Moura MD; Gomez RS
    J Oral Maxillofac Surg; 2005 Jan; 63(1):20-4. PubMed ID: 15635552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Noninvasive monitoring of changes in the structure and function of masseter muscles after the injection of botulinum toxin type A].
    Guo Z; Diao X; Xia W; Liu T; Chen Y; Zheng J; Zhou Z; Yang P; Zhu J
    Zhonghua Zheng Xing Wai Ke Za Zhi; 2016 Nov; 32(6):437-40. PubMed ID: 30067323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients.
    Lee SH; Wee SH; Kim HJ; Yeo UC; Lee NH; Lee SW; Cho SB
    J Dermatolog Treat; 2013 Apr; 24(2):133-6. PubMed ID: 21888570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Botulinum Toxin Injections for Masseter Reduction in East Asians.
    Cheng J; Hsu SH; McGee JS
    Dermatol Surg; 2019 Apr; 45(4):566-572. PubMed ID: 30883483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guidelines for Botulinum Neurotoxin Injection for Facial Contouring.
    Yi KH; Lee HJ; Hur HW; Seo KK; Kim HJ
    Plast Reconstr Surg; 2022 Sep; 150(3):562e-571e. PubMed ID: 35759641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonging the duration of masseter muscle reduction by adjusting the masticatory movements after the treatment of masseter muscle hypertrophy with botulinum toxin type a injection.
    Wei J; Xu H; Dong J; Li Q; Dai C
    Dermatol Surg; 2015 Jan; 41 Suppl 1():S101-9. PubMed ID: 25548838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of botulinum toxin (botox) in the management of masseter muscle hypertrophy: a simplified technique.
    Andrade NN; Deshpande GS
    Plast Reconstr Surg; 2011 Jul; 128(1):24e-26e. PubMed ID: 21701301
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study.
    Seok J; Koh YG; Hong JK; Yun SH; Kim DH; Son HS; Choi SY; Yoo KH; Lee YW; Kim BJ
    Dermatol Surg; 2024 Jun; 50(6):527-533. PubMed ID: 38518110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternative Clinical Indications of Botulinum Toxin.
    Alster TS; Harrison IS
    Am J Clin Dermatol; 2020 Dec; 21(6):855-880. PubMed ID: 32651806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrophysiologic change and facial contour following botulinum toxin A injection in square faces.
    Lee CJ; Kim SG; Kim YJ; Han JY; Choi SH; Lee SI
    Plast Reconstr Surg; 2007 Sep; 120(3):769-778. PubMed ID: 17700130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of two formulations of botulinum toxin type A for masseter reduction: a split-face comparison study.
    Wanitphakdeedecha R; Ungaksornpairote C; Kaewkes A; Sathaworawong A; Lektrakul N; Manuskiatti W
    J Dermatolog Treat; 2017 Aug; 28(5):443-446. PubMed ID: 27884065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RimabotulinumtoxinB versus OnabotulinumtoxinA in the treatment of masseter hypertrophy: a 24-week double-blind randomized split-face study.
    Lee DH; Jin SP; Cho S; Feneran A; Youn CS; Won CH; Park GH; Kim BW; An J; Chang SE; Lee MW
    Dermatology; 2013; 226(3):227-32. PubMed ID: 23774030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The change of maximum bite force after botulinum toxin type a injection for treating masseteric hypertrophy.
    Ahn KY; Kim ST
    Plast Reconstr Surg; 2007 Nov; 120(6):1662-1666. PubMed ID: 18040203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A.
    Nikolis A; Enright KM; Rudolph C; Cotofana S
    J Cosmet Dermatol; 2020 Jun; 19(6):1294-1300. PubMed ID: 32338450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aesthetic uses of botulinum toxin A.
    Niamtu J
    J Oral Maxillofac Surg; 1999 Oct; 57(10):1228-33. PubMed ID: 10513870
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessment of changes in masseter muscle by three-dimensional close-range photogrammetry after Botulinum toxin type-A injection: A case report with review of literature.
    Bayrak NB; Zeybek M; Sanlioglu I; Dolanmaz D
    J Pak Med Assoc; 2019 Mar; 69(3):418-422. PubMed ID: 30890839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Anatomical Basis of Paradoxical Masseteric Bulging after Botulinum Neurotoxin Type A Injection.
    Lee HJ; Kang IW; Seo KK; Choi YJ; Kim ST; Hu KS; Kim HJ
    Toxins (Basel); 2016 Dec; 9(1):. PubMed ID: 28042813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.